The SURMOUNT-1 Phase 3 trial published in the New England Journal of Medicine demonstrated 20.9% mean body weight reduction at 72 weeks on tirzepatide 15mg weekly versus 3.1% with placebo
The treatments included PBS, oridonin, orid-liposome, and TLR2 pep-orid-liposome, each administered intravenously at a dose of 5 mg/kg body weight
Overcoming Plateaus: If your weight loss has stalled on a GLP-1 medication alone, adding a metabolic support like topiramate may help restart progress
However, it is relatively complex and time-consuming to perform, requiring a high level of expertise and experience (Prior et al
Insider Tip: Peptides typically arent very bioavailable (even when administered intravenously or subcutaneously), but TB-500 may have improved bioavailability over TB4 due to its smaller size and stabilizing N-terminal acetylation.24 25 What are TB4 and TB-500 peptides used for